TY - JOUR
T1 - Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2
AU - Okawa, Takaomi
AU - Naomoto, Yoshio
AU - Nobuhisa, Tetsuji
AU - Takaoka, Munenori
AU - Motoki, Takayuki
AU - Shirakawa, Yasuhiro
AU - Yamatsuji, Tomoki
AU - Inoue, Hiroyasu
AU - Ouchida, Mamoru
AU - Gunduz, Mehmet
AU - Nakajima, Motowo
AU - Tanaka, Noriaki
PY - 2005/11/15
Y1 - 2005/11/15
N2 - Purpose: Both heparanase and cyclooxygenase-2 (COX-2) are thought to play critical roles for tumor malignancy, including angiogenesis, although it is unknown about their relationship with each other in cancer progression. We hypothesized that they may link to each other on tumor angiogenesis. Experimental Design: The expressions of heparanase and COX-2 in 77 primary human esophageal cancer tissues were assessed by immunohistochemistry to do statistical analysis for the correlation between their clinicopathologic features, microvessel density, and survival of those clinical cases. Human esophageal cancer cells were transduced with heparanase cDNA and used for reverse transcription-PCR and Western blot to determine the expression of heparanase and COX-2. COX-2 promoter vector and its deletion/mutation constructs were also used along with transduction of heparanase cDNA for luciferase assay. Results: Heparanase and COX-2 protein expression exhibited a similar pattern in esophageal tumor tissues, and their expression correlated with tumor malignancy and poor survival. Their expression also revealed a significant correlation with high intratumoral microvessel density. Up-regulation of COX-2 mRNA and protein was observed in esophageal cancer cells transfected with heparanase cDNA. COX-2 promoter was activated after heparanase c DNA was transduced and the deletion/mutation of three transcription factor (cyclic AMP response element, nuclear factor-κB, and nuclear factor-interleukin-6) binding elements in COX-2 promoter strongly suppressed its activity. Conclusion: Our results suggest that heparanase may play a novel role for COX-2-mediated tumor angiogenesis.
AB - Purpose: Both heparanase and cyclooxygenase-2 (COX-2) are thought to play critical roles for tumor malignancy, including angiogenesis, although it is unknown about their relationship with each other in cancer progression. We hypothesized that they may link to each other on tumor angiogenesis. Experimental Design: The expressions of heparanase and COX-2 in 77 primary human esophageal cancer tissues were assessed by immunohistochemistry to do statistical analysis for the correlation between their clinicopathologic features, microvessel density, and survival of those clinical cases. Human esophageal cancer cells were transduced with heparanase cDNA and used for reverse transcription-PCR and Western blot to determine the expression of heparanase and COX-2. COX-2 promoter vector and its deletion/mutation constructs were also used along with transduction of heparanase cDNA for luciferase assay. Results: Heparanase and COX-2 protein expression exhibited a similar pattern in esophageal tumor tissues, and their expression correlated with tumor malignancy and poor survival. Their expression also revealed a significant correlation with high intratumoral microvessel density. Up-regulation of COX-2 mRNA and protein was observed in esophageal cancer cells transfected with heparanase cDNA. COX-2 promoter was activated after heparanase c DNA was transduced and the deletion/mutation of three transcription factor (cyclic AMP response element, nuclear factor-κB, and nuclear factor-interleukin-6) binding elements in COX-2 promoter strongly suppressed its activity. Conclusion: Our results suggest that heparanase may play a novel role for COX-2-mediated tumor angiogenesis.
UR - http://www.scopus.com/inward/record.url?scp=28144446990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28144446990&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-1103
DO - 10.1158/1078-0432.CCR-05-1103
M3 - Article
C2 - 16299228
AN - SCOPUS:28144446990
SN - 1078-0432
VL - 11
SP - 7995
EP - 8005
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 22
ER -